## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027**
- Source: Business Wire | 20251211T121006 | Neutral | Relevance: 100%
- Sarepta Therapeutics, Inc. has announced a refinancing of approximately $291.4 million of its 1.25% convertible senior notes due 2027. The company will exchange these notes for new 4.875% convertible senior notes due 2030 and approximately $31.6 million in cash. This transaction is expected to close around December 18, 2025, and will result in a total of $893.4 million in aggregate principal amount of the new 4.875% Convertible Senior Notes due 2030.

**2. 683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT**
- Source: MarketBeat | 20251213T170955 | Neutral | Relevance: 100%
- 683 Capital Management LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 309.1% in Q2, making it the 23rd largest holding. Despite this, Sarepta reported a quarterly EPS miss and a year-over-year revenue decline, leading analysts to maintain a mixed "Hold" rating with an average price target of $33.68.

**3. Sarepta CEO given first equity award in 8 years**
- Source: The Business Journals | 20251212T100933 | Neutral | Relevance: 100%
- Sarepta Therapeutics CEO Doug Ingram has been granted his first equity awards in eight years. These awards are performance-based, tied to his tenure at Sarepta and the company's performance over the coming years. This move aims to incentivize Ingram's continued leadership and the company's future success.

**4. Sarepta Therapeutics stock falls after debt exchange announcement**
- Source: Investing.com | 20251211T151006 | Somewhat-Bearish | Relevance: 100%
- Sarepta Therapeutics stock dropped 3.7% after the company announced a debt exchange agreement. This deal involves restructuring approximately $291.4 million of its 1.25% convertible senior notes due 2027 into new 4.875% convertible senior notes due 2030, plus a cash component. The transaction is expected to finalize on December 18th.

**5. Sarepta to refinance $291M of existing notes due 2027**
- Source: MSN | 20251211T131006 | Somewhat-Bullish | Relevance: 100%
- Sarepta Therapeutics plans to refinance $291 million of its existing 1.125% convertible senior notes due in 2027 by offering new convertible senior notes due in 2029. The refinancing aims to manage its debt structure and financial obligations related to these securities.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 3 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 37.0% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.4 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 3.4% to 0.6% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.63x), long-term trend not supportive. RSI neutral at 55. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.62% (CS: 34) | Neutral |
| RSI_14 | 54.6 | Neutral |
| MACD Histogram | 0.25 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 0.630x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.53
- **Stop Loss:** $18.83 (12.5% risk)
- **Target:** $24.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 370
- **Position Value:** $7,966.10
- **Portfolio %:** 7.97%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*